Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gunnarsson

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Annals of Neurology|June 26, 2024
COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with RituximabFredrik Piehl, Peter Alping, Suvi Virtanen, et al.
Annals of Clinical and Translational Neurology|August 22, 2022
COVID-19 clinical outcomes and DMT of MS patients and population-based controlsElisa Longinetti, Hannah Bower, Kyla A McKay, et al.
European Journal of Neurology|June 9, 2021
Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis-a presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
The Lancet. Neurology|July 16, 2022
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trialAnders Svenningsson, Thomas Frisell, Joachim Burman, et al.
JAMA Neurology|June 18, 2019
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysisClaire Bridel, Wessel N van Wieringen, Henrik Zetterberg, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Annals of Neurology|June 26, 2024
COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with RituximabFredrik Piehl, Peter Alping, Suvi Virtanen, et al.
Annals of Clinical and Translational Neurology|August 22, 2022
COVID-19 clinical outcomes and DMT of MS patients and population-based controlsElisa Longinetti, Hannah Bower, Kyla A McKay, et al.
European Journal of Neurology|June 9, 2021
Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis-a presymptomatic case-control studyViktor Grut, Martin Biström, Jonatan Salzer, et al.
The Lancet. Neurology|July 16, 2022
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trialAnders Svenningsson, Thomas Frisell, Joachim Burman, et al.
JAMA Neurology|June 18, 2019
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysisClaire Bridel, Wessel N van Wieringen, Henrik Zetterberg, et al.
Pageof 4